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Introduction
Death and morbidity from malaria are on the increase largely as a result of parasite drug resistance (Snow et al., 2001) . Consequently there are more people dying of malaria now than there were 20 years ago.
Recognition of this problem by the international community and the engagement of the pharmaceutical industry and other key stakeholders, has catalysed the concerted search for new antimalarial drugs with novel targets (Biagini et al., 2005; Biagini et al., 2003; Edwards and Biagini, 2006) . Acridine-based drugs have a long history in malaria chemotherapy. Mepacrine was the first synthetic antimalarial blood schizontocide used clinically (Wernsdorfer and Payne, 1991) whilst the related drug pyronaridine, has been used for nearly 20 years as a monotherapy to treat malaria in China (Shao, 1990 ).
More recently PYRAMAX®, a pyronaridine-artesunate combination treatment is currently undergoing phase III clinical trials (mmv.org). In addition, acridine congeners including the acridones (Basco et al., 1994; Winter et al., 2006) and dihydroacridinediones (Dorn et al., 2001; Durckheimer et al., 1980) , have also demonstrated potent antimalarial activity, in some cases with good in vitro therapeutic indices (Winter et al., 2006 ).
Many acridine-based compounds can bind to heme (e.g. (Auparakkitanon et al., 2006; Auparakkitanon et al., 2003; Chou and Fitch, 1993; Dorn et al., 2001; Dorn et al., 1998) ), the by-product of parasite haemoglobin digestion. Clinically relevant acridines such as quinacrine and pyronaridine are believed to confer almost all of their antimalarial activity through this interaction, by preventing the crystallization of heme (Auparakkitanon et al., 2006; Dorn et al., 1998) . However not all acridine-based inhibitors kill the parasite via this route. Some 9-aniloacridines for example have been shown to exert their antimalarial activity through the inhibition of DNA topoisomerase II (Auparakkitanon and Wilairat, 2000; Gamage et al., 1994) .
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Whilst some dihydroacridinediones have been reported to inhibit the malaria parasite respiratory pathway, causing a reduction in whole cell O 2 consumption (Suswam et al., 2001) .
A role for parasite mitochondria is implicated by a degree of cross resistance between some dihydroacridinediones and atovaquone (Suswam et al., 2001) , although this relationship is not conclusive and has not been demonstrated with allelically exchanged parasite lines. Furthermore, studies performed on beefheart mitochondria revealed that alkyl-acridones inhibit a number of mitochondrial functions including Complex I (Oettmeier et al., 1992) , Complex III (Oettmeier et al., 1994) (bc 1 complex, the membrane-bound complex containing two distinct quinone binding sites, Q o (quinol oxidation) and Q i (quinone reduction)) and the ATP/ADP translocase (Oettmeier et al., 1995) . By virtue of their structural similarity to alkyl-acridones, the potent (pM) antimalarial activity of newly synthesised haloalkoxyacridones (Winter et al., 2006) has been attributed to inhibition of mitochondrial bc 1 complex, although it is possible that for some of these compounds antimalarial activity is a consequence of heme-binding.
In this study, we have investigated the antimalarial mode of action of two dihydroacridinediones, floxacrine and WR249685 (the S enantiomer of WR243246), developed by the Walter Reed Army Institute of Research ( Fig. 1 (Dorn et al., 2001; Kesten et al., 1992; Raether and Fink, 1979; Raether and Fink, 1982; Schmidt, 1979) ). Both of these compounds show heme binding and bc 1 inhibitory properties however, whilst floxacrine kills parasites via a heme-mediated process, WR249685 is shown here to be a highly selective inhibitor of the Q o of the P. falciparum bc 1 complex. The molecular nature of the selectivity of these drugs and their potential as novel antimalarial drugs is discussed.
Materials and Methods
Parasite, culture, and drug sensitivity assays. P. falciparum (3D7 strain) cultures consisted of a 2 % suspension of O+ erythrocytes in RPMI 1640 medium (R8758, glutamine, and NaHCO 3 ) supplemented with 10 % pooled human AB+ serum, 25 mM HEPES (pH 7.4), and 20 µM gentamicin sulfate (Trager and Jensen, 1976) . Cultures were grown under a gaseous headspace of 4% O 2 , 3% CO 2 in N 2 at 37°C. Parasite growth was synchronized by treatment with sorbitol (Lambros and Vanderberg, 1979) . The sensitivity of P.
falciparum-infected erythrocytes to various drugs was determined using the [ 3 H]-hypoxanthine incorporation method (Desjardins et al., 1979) with an inoculum size of 0.5 % parasitemia (ring stage) and 1% hematocrit.
IC 50 s were calculated by using the four-parameter logistic method (Grafit program; Erithacus Software, U.K.). To determine whether the antimalarial activity of two drugs is additive, antagonistic or synergistic, parasite growth was tested by titration of the two drugs at fixed ratios proportional to their IC 50 s. The fractional inhibitory concentrations of the resulting IC 50 s were plotted as isobolograms (Berenbaum, 1978) .
Inhibition of in vitro hemozoin formation. Assays were performed based on the methods by Bray et al. (Bray et al., 1999) and Stead et al., (Stead et al., 2001) . Briefly, an aliquot of ghost erythrocyte membrane (100 µl) and FPIX (100 µl of 3 mM in 0.1 M NaOH) were mixed with an aliquot of 1 M HCl (10 µl) and sodium acetate (500 mM, pH 5.2) was added to give a volume of 900 µl in each tube. A series of drug concentrations were prepared in water and 100 µl of each was added to the appropriate samples. Samples were mixed and incubated for 48 h at 37°C, with occasional mixing. After incubation, samples were centrifuged (15,000 g, 15 min, 21°C) and the hemozoin pellet repeatedly washed with 2% w/v SDS in 0.1 M sodium bicarbonate, pH 9.0, until the supernatant was clear (usually 3-4 times). After the final wash, the supernatant was removed and the pellet was resuspended in 1 ml of 0.1 M NaOH and incubated for a further 1 h at room temperature. The hemozoin content was determined by measuring the absorbance at 400. The MOL #45120
concentration of drug required to produce 50% inhibition of hemozoin production (IC 50 ) was determined graphically as described for the drug sensitivity assays.
Determination of heme-drug dissociation constants. Heme-drug equilibrium constants were determined based on a UV-visible spectroscopic method (Egan et al., 1997) . To provide a strictly monomeric heme (ferriprotoporphyrin IX) species in solution, heme (6 µM) was prepared in a HEPES (20 mM, pH 7.2) buffered solution of 40 % (v/v) DMSO (Egan et al., 1997) . UV-visible titrations of antimalarial drugs chloroquine, amodiaquine, floxacrine and WR249685 were performed monitoring the Soret band of the porphyrin (390-460 nm). The resulting titration curves were analysed using a non-linear curve fitting programme (Pro-Fit) and thermodynamic parameters were derived from modelling, assuming a 1:1 complexation of drug and heme (Egan et al., 1997; Marques et al., 1996) . Microsomes were resuspended in 2× volume of 0.12 M Tris, pH 7.4, and stored frozen (−80 °C) in 1 ml aliquots at 80°C.
Preparation of yeast cytochrome b mutants.
Generation of mutant strains and preparation of crude mitochondrial membranes was performed as described previously (Fisher et al., 2004b) .
Bovine mitochondrial membrane preparation. Bovine mitochondrial membranes (Keilin-Hartree particles)
were prepared as described by Kuboyama et al (Kuboyama et al., 1972) Rat liver microsome preparation. Adult male Wistar rats were obtained from Charles River Laboratories (Margate, Kent, UK). Wistar rat (RLM) liver microsomes were prepared from male rats (125-170g) as described by Gill et al., (Gill et al., 1995) .
Preparation of decylubiquinol. The artificial quinol electron donor was prepared based on the method of Fisher et al., (Fisher et al., 2004b) . Briefly, 2,3-dimethoxy-5-methyl-n-decyl-1,4-benzoquinone (decylubiquinone), an analogue of ubiquinone, was dissolved (10 mg) in 400 µl of nitrogen-saturated hexane.
An equal volume of aqueous 1.15 M sodium dithionite was added, and the mixture shaken vigorously until colourless. The upper, organic phase was collected, and the decylubiquinol recovered by evaporating the This article has not been copyedited and formatted. The final version may differ from this version. and stored in aliquots at -80 °C. Decylubiquinol concentration was determined spectrophotometrically from absolute spectra, using ε 288-320 = 4.14 mM -1 cm -1 .
Measurement of bc 1 activity. Cytochrome c reductase activity measurements were assayed in 50 mM potassium phosphate (pH 7.5), 2 mM EDTA, 10 mM KCN, and 30 µM equine cytochrome c (Sigma) at room temperature (Fisher et al., 2004b) . Cytochrome c reductase activity was initiated by the addition of decylubiquinol (50 µM). Reduction of cytochrome c was monitored in a Cary 4000 spectrophotometer at 550 versus 542 nm. Initial rates (computer-fitted as zero-order kinetics) were measured as a function of decylubiquinol concentration. The cytochrome b content of membranes was determined from the dithionitereduced minus ferricyanide-oxidized difference spectra, using ε 562-575 = 28.5 mM -1 cm -1 (Vanneste, 1966) .
Turnover rates of cytochrome c reduction were determined using ε 550-542 =18.1 mM -1 cm -1 (Margoliash and Walasek, 1967) .
Inhibitors of bc 1 activity were added without prior incubation. DMSO in the assays did not exceed 0.3 % (v/v). IC 50 s were calculated using the four-parameter logistic method (Grafit program; Erithacus Software, U.K.). The equilibrium dissociation constant (K i ) of inhibitor binding to bc 1 was determined using the Cheng-Prusoff equation (Cheng and Prusoff, 1973) .
Real-time single-cell monitoring of membrane potential (∆Ψ m ). The rhodamine derivative, TMRE
(tetramethylrhodamine ethyl ester), was used to monitor the membrane potential (∆Ψ m ) of the plasmamembrane and mitochondria of malaria infected red blood cells . TMRE is cationic and reversibly accumulates inside energised membranes according to the Nernst equation. 
Dihydroacridinedione docking into P. falciparum cytochrome b (Q o ).
A predicted model of the P.
falciparum cytochrome b of the bc 1 complex was constructed with SWISS-MODEL using bovine cytochrome b PDB coordinate sets 1ntmC, 1sqxC, 1l0nC, 1ntkC and 1be3c as the structural templates. In silico docking was performed using Autodock 3.05 (Morris et al., 1998) Heme-drug equilibrium constants were determined for CQ, amodiaquine (AQ), floxacrine and WR249685 by measuring the shift of the heme Soret band on titration of drugs. In buffered DMSO (40 % (v/v)) solutions, the heme-drug dissociation constants (K i ) were calculated to be; 1.38 µM for CQ, 1.55 µM for AQ, 1.87 µM for floxacrine and 31.74 µM for WR249685 (values means of two independent determinations).
The relative poor heme binding affinity of WR249685 was in contrast to its potent in vitro antimalarial activity (IC 50 15 nM) which was comparable to that for CQ (IC 50 7.4 nM), AQ (IC 50 4.5 nM) and significantly better than that for floxacrine (IC 50 140 nM, Table 1 ).
Dihydroacridinediones inhibit P. falciparum bc 1 activity. The ability of floxacrine and WR249685 to inhibit bc 1 complex activity was determined in a number of species and compared to that of well known bc 1 inhibitors ( Fig. 1) . For all species, bc 1 activity was determined by monitoring the reduction of cytochrome c with decylubiquinol (QH 2 ) as electron donor.
P. falciparum bc 1 activity exhibited Michaelis-Menten kinetics with an apparent concentration of substrate leading to half-maximal velocity (K m ) for QH 2 of 6.2 ± 2 µM reaching a maximum/limiting velocity (V max ) of This article has not been copyedited and formatted. The final version may differ from this version. (Fry and Pudney, 1992) , all inhibitory assays were performed in the absence of surfactant.
Inhibition profiles of bc 1 complexes from bovine heart, rat liver, human liver and P. falciparum are described in Table 1 . The bc 1 complexes from all species were shown to be similarly sensitive to the well known bc 1 inhibitors stigmatellin, and myxothiazol. The antimalarial drug atovaquone displayed selective inhibition for P. falciparum bc 1 complex (IC 50 3 ± 2 nM, K i = 0.3 nM) over mammalian bc 1 complexes. Interestingly however, human and bovine bc 1 activity was observed to be more sensitive to atovaquone (IC 50 72 and 83 nM, respectively) compared to rat liver bc 1 activity (IC 50 406 nM). Similarly, albeit more modestly, the pyridone GW844520, displayed selective toxicity for the parasite enzyme (IC 50 32 nM) over mammalian enzymes (IC 50 's ranging 51 -353 nM). The dihydroacridinedione WR249685 was shown to be selective exclusively for P. falciparum bc 1 complex (IC 50 3 nM, K i = 0.3 nM). Notably, the in vitro therapeutic index (TI) for this inhibitor against human bc 1 was >4600. This dramatic selectivity is significantly higher than that observed with atovaquone (TI = 24) or with the pyridone GW844520 (TI = 5). Floxacrine was shown to have moderate inhibitory activity against cross-species bc 1 activities (IC 50 's ranging 328-1458 nM), but without any selectivity over the P. falciparum enzyme.
This article has not been copyedited and formatted. The final version may differ from this version. (Fisher and Meunier, 2005; Korsinczky et al., 2000; Srivastava et al., 1999; Syafruddin et al., 1999) . The G143A mutation confers dramatic resistance to heme proximal Q o inhibitors such as myxothiazol (Fisher et al., 2004a; Fisher and Meunier, 2005) . As expected, atovaquone was shown to have potent bc 1 inhibitory activity against wild type yeast (IC 50 3 nM) and G143A mutants (IC 50 27 nM), whilst the Y279S mutation conferred significant resistance (IC 50 2689 nM, Table 2 ). Interestingly, the Y279S mutation was also associated with a moderate increase in tolerance to the pyridone GW844520, floxacrine and WR249685 (Table 2) . Taken 
Drug combination analysis of atovaquone with WR249685.
As the data indicate that both atovaquone and WR249685 target the bc 1 complex of P. falciparum mitochondrial ETC, it was of interest to determine whether the two inhibitors would compete for ligand binding resulting in antagonistic inhibition. To do this, we performed isobole analysis of growth inhibition by titration of the drugs at fixed ratios proportional to their IC 50 's. The resultant isobologram of atovaquone and WR249685 is suggestive of a possible antagonistic interaction (Fig. 4) .
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Discussion
In this study, the mode of action of two potent antimalarial dihydroacridinediones has been investigated.
Historically, acridine derivatives have been considered to owe their antimalarial activity to their ability to bind heme. Therefore we first investigated the relative heme binding properties of floxacrine and WR249685. Thermodynamic analysis of heme-binding revealed that both inhibitors could bind to heme with a rank order relative to other well known heme binding drugs of; CQ > AQ> floxacrine >> WR249685. The heme-drug equilibrium constants for CQ and AQ closely match those reported previously by other workers (Egan et al., 1997) . CQ, floxacrine and to a lesser extent WR249685 were shown to be able to inhibit in vitro hemozoin formation. This data is consistent with that of Dorn et al., (Dorn et al., 2001 ), which showed a nM) whilst displaying a >20 fold poorer affinity for heme compared to the other antimalarial drugs.
As concluded by Dorn et al., (Dorn et al., 2001 ), it appears that heme does not play a major role in the mode of action of all dihydroacridinediones. Given that related dihydroacridinediones have been shown to affect respiration of P. falciparum (Suswam et al., 2001 ), we next investigated whether the mode of action of WR249685 was related to the inhibition of respiratory components.
Mild cross resistance (4-9 fold) of a dihydroacridinedione (WR243251) has been described in P. falciparum strains displaying 8,700 -23,000 increase fold resistance in atovaquone (Suswam et al., 2001) . Although these parasite lines also displayed an increase in resistance to other antimalarials such as CQ, as the site of This article has not been copyedited and formatted. The final version may differ from this version. action of atovaquone is the bc 1 complex (Fry and Pudney, 1992) , this respiratory component was chosen for investigation.
The bc 1 complex is a membrane bound enzyme catalysing the transfer of electrons from ubiquinol to cytochrome c coupled with the concomitant vectorial translocation of protons across the inner mitochondrial membrane (Crofts, 2004) . The catalytic core of the enzyme is made up of cytochrome b, cytochrome c 1 and the Rieske iron-sulphur protein (ISP). The catalytic mechanism, known as the Q-cycle (Crofts, 2004; Mitchell, 1975) involves two distinct quinone bindinding sites within cytochrome b, the quinol oxidation site Q o and the quinone reduction site Q i (Crofts, 2004) . These two sites are situated on opposite sides of the membrane linked by a transmembrane electron pathway via hemes b l and b h (Crofts, 2004) . A number of inhibitors selective for bc 1 Q o and Q i sites have been developed over recent years, most notably to control crop and human pathogens (Crofts et al., 1999; Esser et al., 2004; Fisher et al., 2004a ).
In our study, stigmatellin, which binds in the b l distal domain of Q o (close to the docking site of ISP) (Crofts et al., 1999) and myxothiazol, which binds in the b l -proximal position (Crofts et al., 1999) , were both shown to be potent broad spectrum bc 1 inhibitors (Table 1) . Interestingly however, inhibition of bc 1 activity by the dihydroacridinediones, pyridone and naphthoquinone was highly species selective (Table 1) .
Species selectivity was most notably demonstrated by WR249685, which displayed a K i for P. falciparum of 0.3 nM and an in vitro therapeutic index (TI) against human bc 1 of >4600 (Table 1) . Yeast carrying the Y279S mutation in cytochrome b (corresponding to the Y268S mutation in P. falciparum conferring atovaquone resistance (Fisher and Meunier, 2005; Korsinczky et al., 2000; Srivastava et al., 1999; Syafruddin et al., 1999) ) were observed to be less sensitive to WR249685 suggesting that Q o is the binding site for this
This article has not been copyedited and formatted. The final version may differ from this version. X-ray crystallography has shown that the overall fold of the α -carbon backbone of cytochrome b is highly conserved in prokaryotic and eukaryotic organisms (Fig. 5a) . However, despite the high degree of sequence and structural conservation, there are notable differences in key regions of the malaria parasite Q o site.
Significantly, a homology model of the P. falciparum cytochrome b (constructed with SWISS-MODEL using bovine cytochrome b atomic coordinates as the structural template) suggests that the four residue deletion in the cd2 helix results in a 13Å displacement of this structural element when compared to the mammalian enzyme (Fig. 5b) . Similarly, the α -carbon atom of the N-terminal proline of the ef helix (containing the catalytically essential 'PEWY' motif) is predicted to be displaced by 2Å in comparison to the mammlian enzyme. Other important differences include the replacement of lysine (269) the inhibitor and the E-ef linker region (residues 236-241) of the cytochrome (Fig. 5a, 6b ), a region of low sequence identity between Plasmodium and mammalian cytochrome b. The E-ef linker has not previously been recognised as a component of the Q o site in the elucidated bc 1 crystal structures, and thus may explain the very high degree of selectivity of WR249685 for the Plasmodium enzyme.
It is necessary however to be circumspect in the interpretation of the modelling data. It should be noted that 'structural' water molecules at Q o were not included in the modelling process, and these may influence the binding energy and positioning of WR249685. Additionally, the Rieske ISP headgroup was omitted during the modelling process, which has two important consequences. Firstly, the loss of a potential hydrogen-bond donor to the Q o site via [2Fe-2S] cluster ligand His-161 (Esser et al., 2004) and, secondly, the steric volume occupied by the ISP is absent, which may allow for non-physiological but otherwise energetically favourable in silico docking of bulky inhibitors at Q o .
The 5.6-fold increase in IC 50 for atovaquone in rat liver microsome preparations compared to the human equivalent (Table 1) is, at first sight, surprising given the sequence homology between these species in the cd1 and ef regions of cytochrome b (Fig. 5a ). It is possible that this difference is due to slight variation in the local fold and protein environment around Q o , but a minor change in hydrogen-bonding capacity in the Cterminal region of transmembrane helix C may also weaken the interaction with atovaquone, raising the binding energy required for a stable association. Notably, bovine and human cytochrome b possess a potenial Q o -site hydrogen bond donor in the forms of Thr-121 and Thr-122 respectively, residues which are absent in rat. In addition, there is conservative variation in the aliphatic composition of the F1 helix between This article has not been copyedited and formatted. The final version may differ from this version. these three species, which may result in an unfavourable steric environment for atovaquone binding in rat cytochrome b.
In a similar fashion the pyridone GW844520, shown to be specific for the bc 1 Q o site (Table 2) , also displayed a 2 fold selectivity for human bc 1 over the rat enzyme (Table 1) , with an in vitro therapeutic index (TI) against human bc 1 of only 5 ( Table 1 ). The drug development of this particular pyridone was terminated in late 2005 by the Medicines for Malaria Venture (MMV) due to toxicity issues (www.mmv.org). Currently a new pyridone (GSK932121A) is being developed with reduced toxicity. It will be interesting to establish whether this compound has an improved TI against human bc 1 .
To our knowledge this study is the first to report human liver bc 1 activity. At this stage we have no idea of inter-patient variation of bc 1 activities, nonetheless our data indicate that rat liver enzyme is a poor model for human bc 1 and therapeutic indices generated from rat liver data should be treated with a degree of caution.
Addition of dihydroacridinediones to malaria infected erythrocytes was shown to cause the depolarisation of mitochondrial ∆ Ψ m (Fig. 3) . We hypothesise that the depolarisation of mitochondrial ∆ Ψ m leads to a loss mitochondrial function and parasite death. Given that during the intraerythrocytic stage of the malaria life cycle, the parasite relies mainly on fermentation of glucose, the essential role(s) of the mitochondrion is not known, but it probably includes orotate production for pyrimidine biosynthesis (Gutteridge et al., 1979; Hammond et al., 1985) and Ca 2+ homeostasis (Gazarini and Garcia, 2004; Uyemura et al., 2000) .
Furthermore the close juxtaposition of the mitochondrion with the plastid suggests an interdependence for essential metabolism (Goodman et al., 2007; Kobayashi et al., 2007) .
This article has not been copyedited and formatted. The final version may differ from this version. operating in reverse (Painter et al., 2007) . We however have questioned these conclusions (Fisher et al., 2008) , and maintain that targeting the proton pumping bc 1 complex leads to a depolarisation of (Daily et al., 2007; van Dooren and McFadden, 2007 ).
This study has described a new class of highly selective P. falciparum inhibitors predicted to target the Q o site of the bc 1 complex. The ability of these compounds to additionally disrupt hemozoin formation makes them attractive inhibitors which merit further drug development. This view is strengthened by the potent pM antimalarial activity displayed by the recently synthesized haloalkoxyacridones (Winter et al., 2006) .
Furthermore, we predict that by assessing the inhibitory activity of these molecules against human bc 1 , it may be possible to circumvent toxicological issues previously encountered during the development of other dihydroacridinediones such as floxacrine (Raether and Fink, 1982 squares below the sequence data identify residues in close contact (< 3.5Å separation, hydrogen bonding or 40Å2 surface contact) with stigmatellin in 1SQX.pdb (Esser et al., 2004) ; filled circles identify residues in This article has not been copyedited and formatted. The final version may differ from this version. Highlighted residues are discussed in the text. This article has not been copyedited and formatted. The final version may differ from this version. a bc 1 activity was determined by monitoring cytochrome c reduction using decylubiquinol as electron donor (see methods). All assays contained 5 nM cyt b. DMSO in the assays did not exceed 0.3 %. All data acquired from multiple observations from at least two separate preparations. IC 50 s were calculated by using the four-parameter logistic method.
